HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Amount
- $350,000
- Closes
- Jan 15, 2027 (in 138 days)
Similar opportunities open now
- HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses in 85 daysUp to $375K
- Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jan 2027
- Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 8 days
- Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jul 2027
- Focused Technology Research and Development (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jan 2028
Classification and identifiers
- Solicitation number
- RFA-NS-25-023
- Assistance listing (CFDA)
- 93.846
Amount
$350,000
Who can apply
Nonprofits, including small and volunteer-run organizations can apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
About this opportunity
This funding opportunity is part of a suite of NOFOs within the NIH HEAL Initiative to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal is to encourage initial translational efforts that will support a drug discovery program and advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program. The scope will therefore be focused on development of assays to support a distinct testing funnel, screening efforts to identify hits, and initial characterization of hits and potential therapeutic agents (including small molecules, biologics, and natural products).